近年のIPF市場の成長の主な要因は、高価格帯のピルフェニドン（エスブリエット）やニンテダニブ（オフェブ）の使用が増え、適応外薬理療法や非薬理療法が支持されるようになったことです。これらの薬剤が承認される以前は、一般的な治療法としてエビデンスに基づくガイドラインで否定的な勧告がなされているにもかかわらず、IPFの治療には安価なコルチコステロイドと免疫抑制剤が使用されていました。
特発性肺線維症の世界市場の成長を牽引する主な要因としては、線維性疾患の有病率の上昇や老年人口の増加などが挙げられます。また、費用対効果の高い医薬品への需要の高まりや、先進的な治療法の導入が市場の成長を後押ししています。さらに、ライフスタイルの変化やニコチン製品の消費量の増加が、市場成長の推進力となっています。さらに、たばこの喫煙はIPFの発症の最も一般的な原因と考えられています。これに伴い、IPFの効果的な管理戦略に関する大衆の健康意識が高まっていることも、市場の成長に好影響を与えています。
また、新薬の登場やIPFの診断・治療法の進歩も、成長を促す要因となっています。これに加えて、広範な研究開発活動や医療インフラの改善も、市場を牽引すると予想される要因の1つです。
さらに、IPFの患者には、薬物療法に加えて、さまざまな非薬物療法も行われています。非薬物療法としては、肺移植、人工呼吸、酸素療法、肺リハビリテーションが最も多く用いられています。一般に、IPFの治療法は、患者の症状や病期、健康状態などに大きく左右されます。
目次
Table of Contents
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Idiopathic Pulmonary Fibrosis Market: Product Outlook
4. Global Idiopathic Pulmonary Fibrosis Market: Sizing and Forecast
4.1 Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026
4.2 Impact of COVID-19 on Global Idiopathic Pulmonary Fibrosis Market
5. Global Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User
5.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Drug Type
5.1.1 Nintedanib - Market Size and Forecast (2016-2026)
5.1.2 Pirfenidone - Market Size and Forecast (2016-2026)
5.1.3 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By End User
5.2.1 Hospitals and Clinics - Market Size and Forecast (2016-2026)
5.2.2 Academics and Research Organization - Market Size and Forecast (2016-2026)
5.2.3 Others - Market Size and Forecast (2016-2026)
6. Global Idiopathic Pulmonary Fibrosis Market: Regional Analysis
6.1 Competitive Scenario of Global Idiopathic Pulmonary Fibrosis Market: By Region
7. North America Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
7.1 North America Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.2 North America Idiopathic Pulmonary Fibrosis Market - Prominent Companies
7.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone and Others)
7.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization and Others)
7.5 North America Idiopathic Pulmonary Fibrosis Market: Country Analysis
7.6 Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Idiopathic Pulmonary Fibrosis Market: By Country
7.8 United States Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.9 United States Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
7.10 Canada Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
7.11 Canada Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8. Europe Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
8.1 Europe Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.2 Europe Idiopathic Pulmonary Fibrosis Market - Prominent Companies
8.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)
8.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)
8.5 Europe Idiopathic Pulmonary Fibrosis Market: Country Analysis
8.6 Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Idiopathic Pulmonary Fibrosis Market: By Country
8.8 Germany Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.9 Germany Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.10 United Kingdom Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.11 United Kingdom Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.12 France Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.13 France Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.14 Italy Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.15 Italy Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
8.16 Spain Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
8.17 Spain Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9. Asia Pacific Idiopathic Pulmonary Fibrosis Market: An Analysis (2016-2026)
9.1 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Idiopathic Pulmonary Fibrosis Market - Prominent Companies
9.3 Market Segmentation By Drug Type (Nintedanib, Pirfenidone, Others)
9.4 Market Segmentation By End User (Hospitals and Clinics, Academics and Research Organization, Others)
9.5 Asia Pacific Idiopathic Pulmonary Fibrosis Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Idiopathic Pulmonary Fibrosis Market: By Country
9.8 China Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.9 China Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9.10 Japan Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.11 Japan Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
9.12 India Idiopathic Pulmonary Fibrosis Market: Size and Forecast (2016-2026), By Value
9.13 India Idiopathic Pulmonary Fibrosis Market Segmentation - By Drug Type, By End User (2016-2026)
10. Global Idiopathic Pulmonary Fibrosis Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Drug Type, 2026
11.2 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By End User, 2026
11.3 Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market - By Region, 2026
12. Competitive Landscape
12.1 Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
12.2 Market Share Analysis
13. Company Analysis
13.1 AbbVie Inc.
13.2 Bristol-Myers Squibb
13.3 F. Hoffman-La Roche Ltd.
13.4 Boehringer Ingelheim
13.5 Merck KGaA
13.6 Gilead Sciences
13.7 Liminal Biosciences
13.8 Cipla
13.9 Galapagos NV
13.10 FibroGen
13.11 Medicinova Inc.
List of Figures
Figure 1: Global Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 3: GDP per Capita Growth (annual %), 2015-2019
Figure 4: World Population 65 Years & Above (% of Total), 2015-2019
Figure 5: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 6: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 7: Global IPF - Number of Drugs by Phase
Figure 8: Global Idiopathic Pulmonary Fibrosis Market- By Drug Type Market Share, 2020 & 2026
Figure 9: Global Idiopathic Pulmonary Fibrosis Market- By Nintedanib, By Value (USD Million), 2016-2026
Figure 10: Global Idiopathic Pulmonary Fibrosis Market- By Pirfenidone, By Value (USD Million), 2016-2026
Figure 11: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026
Figure 12: Global Idiopathic Pulmonary Fibrosis Market- By End User Market Share, 2020 & 2026
Figure 13: Global Idiopathic Pulmonary Fibrosis Market- By Hospitals and Clinics, By Value (USD Million), 2016-2026
Figure 14: Global Idiopathic Pulmonary Fibrosis Market- By Academics and Research Organization, By Value (USD Million), 2016-2026
Figure 15: Global Idiopathic Pulmonary Fibrosis Market- By Others, By Value (USD Million), 2016-2026
Figure 16: Global Idiopathic Pulmonary Fibrosis Market- By Region Market Share, 2020 & 2026
Figure 17: North America Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 18: North America Current health expenditure(% of GDP)2014-2018
Figure 19: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 20: North America Population ages 65 and above (% of total Population), 2016-2020
Figure 21: North America Idiopathic Pulmonary Fibrosis company market share (%), 2020
Figure 22: North America Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 23: North America Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 24: Market Opportunity Chart of North America Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)
Figure 25: North America Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
Figure 26: United States Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 27: United States Distribution of Diagnosed IPF Patients, 2020
Figure 28: United States Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 29: United States Population aged 65 and above (% of total Population), 2016-2020
Figure 30: United States Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 31: United States Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 32: Canada Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 33: Canada Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 34: Canada Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 35: Canada Population aged 65 and above (% of total Population), 2016-2020
Figure 36: Canada Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 37: Canada Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 38: Europe Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 39: Europe Distribution of Diagnosed IPF Patients, 2020
Figure 40: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 41: European Countries Population ages 65 and above (% of total Population), 2020
Figure 42: Europe Idiopathic Pulmonary Fibrosis company market share (%), 2020
Figure 43: Europe Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 44: Europe Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 45: Market Opportunity Chart of Europe Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year 2016-2026)
Figure 46: Europe Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
Figure 47: Germany Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 48: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 49: Germany Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 50: Germany Urban population growth,(Annual %) 2015-2020 (In %)
Figure 51: Germany Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 52: Germany Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 53: United Kingdom Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 54: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 55: United Kingdom Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 56: United Kingdom Population ages 65 and above (% of total Population), 2016-20
Figure 57: United Kingdom Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 58: United Kingdom Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 59: France Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 60: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 61: France Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 62: France Population ages 65 and above (% of total Population), 2016-20
Figure 63: France Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 64: France Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 65: Italy Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 66: Italy Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 67: Italy Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 68: Italy Population ages 65 and above (% of total Population), 2016-20
Figure 69: Italy Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 70: Italy Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 71: Spain Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 72: Spain Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 73: Spain Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 74: Spain Urban population Growth (Annual %), 2016-2020 (In %)
Figure 75: Spain Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 76: Spain Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 77: Asia Pacific Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 78: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 79: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 80: Asia Pacific Population ages 65 and above, by Countries (% of total Population), 2020
Figure 81: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 82: Asia Pacific Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 83: Market Opportunity Chart of APAC Idiopathic Pulmonary Fibrosis Market- By Country, By Value (Year-2026)
Figure 84: APAC Idiopathic Pulmonary Fibrosis Market- By Country Market Share, 2020 & 2026
Figure 85: China Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 86: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 87: China Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 88: China Population ages 65 and above (% of total Population), 2016-20
Figure 89: China Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 90: China Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 91: Japan Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 92: Japan Europe Distribution of Diagnosed IPF Patients, 2020
Figure 93: Japan Current Healthcare Expenditure as percentage of GDP, 2015-2018 (In %)
Figure 94: Japan Population ages 65 and above (% of total Population), 2016-20
Figure 95: Japan Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 96: Japan Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 97: India Idiopathic Pulmonary Fibrosis Market Size, By Value, 2016-2026 (USD Million)
Figure 98: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 99: India Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 100: India Population ages 65 and above (% of total Population), 2016-20
Figure 101: India Idiopathic Pulmonary Fibrosis Market - By Drug Type, By Value (USD Million), 2016-2026
Figure 102: India Idiopathic Pulmonary Fibrosis Market - By End User, By Value (USD Million), 2016-2026
Figure 103: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Drug Type (Year-2016-2026)
Figure 104: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By End User (Year 2016-2026)
Figure 105: Market Attractiveness Chart of Global Idiopathic Pulmonary Fibrosis Market- By Region (Year 2016-2026)
Figure 106: Global Idiopathic Pulmonary Fibrosis company market share
Figure 107: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Figure 108: AbbVie Inc. Net Income (USD Million), 2016-2020
Figure 109: AbbVie Inc. Sales Revenue Split, By Business Segment (%), FY2020
Figure 110: AbbVie Inc. Sales Revenue Split, By Geography Segment (%), FY2020
Figure 111: Bristol-Myers Squibb Sales Revenues, 2016-2020 (USD Million)
Figure 112: Bristol-Myers Squibb Net Income, 2016-2020 (USD Million)
Figure 113: Bristol-Myers Squibb Sales Revenue Split, By Business Segment (%), FY2020
Figure 114: Bristol-Myers Squibb Sales Revenue Split, By Geography Segment (%), FY2020
Figure 115: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 116: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 117: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 118: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 119: Boehringer Ingelheim Revenues, 2016-2020 (USD Million)
Figure 120: Boehringer Ingelheim Net Income/Loss, 2016-2020 (USD Million)
Figure 121: Boehringer Ingelheim Sales Revenue Split, By Business Segment (%), FY2020
Figure 122: Boehringer Ingelheim Sales Revenue Split, By Geography Segment (%), FY2020
Figure 123: Merck KGaA Sales Revenues, 2016-2020 (USD Million)
Figure 124: Merck KGaA Gross Profit, 2016-2020 (USD Million)
Figure 125: Merck KGaA Sales Revenue Split, By Business Segment (%), FY2020
Figure 126: Merck KGaA Sales Revenue Split, By Geography Segment (%), FY2020
Figure 127: Gilead Sciences, Revenue, 2016-2020 (USD Million)
Figure 128: Gilead Sciences, Net Income 2016-2020 (USD Million)
Figure 129: Gilead Sciences, Revenue, By Business Segment (%), FY2020
Figure 130: Gilead Sciences Revenue, By Geographical Segment (%), FY2020
Figure 131: Liminal Biosciences, Revenue, 2016-2020 (USD Million)
Figure 132: Liminal Biosciences, Net Loss 2016-2020 (USD Million)
Figure 133: Liminal Biosciences, Revenue, By Business Segment (%), FY2020
Figure 134: Liminal Biosciences Revenue, By Geographical Segment (%), FY2020
Figure 135: Cipla Sales Revenues, 2016-2020 (USD Million)
Figure 136: Cipla sales Revenues, By Business Segment (%), FY2020
Figure 137: Cipla sales Revenue, By Geographical Segment (%), FY2020
Figure 138: Galapagos NV Annual Sales Revenue (USD Million), 2016-2020
Figure 139: Galapagos NV sales Revenue, By Geographical Segment (%), FY2020
Figure 140: FibroGen, Revenue, 2016-2020 (USD Million)
Figure 141: FibroGen, Net Loss 2016-2020 (USD Million)
Figure 142: MediciNova, Inc., Total Operating Expenses, 2015-2019 (USD Million)
Figure 143: MediciNova Inc., Net Loss 2015-2019 (USD Million)
List of Tables
Table A Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
Table B Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
Table C Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies
Table D Product Pipeline of Leading Idiopathic Pulmonary Fibrosis Companies - Vicore Pharma
Table E Deals in IPF and severe cough
